Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2020 | Highlights in multiple myeloma at ASCO 2020

Suzanne Lentzsch • 29 May 2020
ASCO 2020
Multiple Myeloma
BOSTON GMMG-CONCEPT KarMMa StaMINA SWOG 1211

Suzanne Lentzsch, MD, PhD, Columbia University, New York, NY, USA, takes us through a selection of the most important studies presented at ASCO 2020 in multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Suzanne Lentzsch

Clinical trial updates in myeloma: managing bone disease, the use of isatuximab, belantamab mafodotin & more
Ola Landgren et al. • 3 May 2024
How to treat AL amyloidosis in 2020? 2:38
How to treat AL amyloidosis in 2020?
Suzanne Lentzsch • 31 Aug 2020
Chemotherapy-free approaches to AL amyloidosis 2:55
Chemotherapy-free approaches to AL amyloidosis
Suzanne Lentzsch • 27 Aug 2020
Unmet needs in amyloidosis 2:50
Unmet needs in amyloidosis
Suzanne Lentzsch • 1 Sep 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals